This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: SEM, MOH, JYNT and HUM
by Zacks Equity Research
Zacks Industry Outlook Highlights: SEM, MOH, JYNT and HUM
Solid Near-Term HMO Industry Prospects on Multiple Tailwinds
by Sapna Bagaria
Health insurers are on a solid ground, given rising demand for Medicare policies, led by the increasing baby boomer population.
Here's Why You Should Add Humana (HUM) to Your Portfolio
by Zacks Equity Research
Riding high on its Medicare line of business and strategic initiatives, Humana (HUM) holds enough potential to reap benefits for investors.
Earnings Preview: The Joint Corp. (JYNT) Q2 Earnings Expected to Decline
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Best MedTech Stocks to Combat Coronavirus Crisis on Strong ROE
by Debanjana Dey
Here are some MedTech stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Riding high on its robust Medicare business line and strategic initiatives, Humana (HUM) holds potential to reap benefits for investors.
Why Should You Hold on to Centene Stock in Your Portfolio?
by Zacks Equity Research
Riding high on a healthy revenue stream and a solid 2020 guidance, Centene (CNC) holds potential to benefit its investors.
Anthem (ANTM) Issues Policies for Safe Coronavirus Testing
by Zacks Equity Research
Anthem (ANTM) issues updates to ease care provider protocols regarding COVID-19 testing
The Joint Corp. (JYNT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 12.50% and 4.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Reduces 2020 Earnings Estimates, Shares Slide
by Zacks Equity Research
Centene (CNC) updates its 2020 outlook that reflects its WellCare buyout and the potential Medicaid rate decrease.
Anthem's (ANTM) Beacon Health Buyout to Bolster Portfolio
by Zacks Equity Research
Anthem (ANTM) carries on with its acquisition spree, the latest being the purchase of Beacon Health.
The Joint Corp. (JYNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 HMO 2019 Outperformers Likely to Retain Beat Streak in 2020
by Srijita Guha
HMO players are poised for growth on the back of higher revenues, membership growth, technological advancements and a solid capital position.
4 Profitable Stocks to Boost Returns Using Net Income Ratio
by Nitish Marwah
Investors always look for companies with a high level of profitability regardless of the present market condition.
Why Hold Strategy is Apt for Universal Health (UHS) Now
by Zacks Equity Research
Universal Health (UHS) is well-positioned to reap benefits for investors on the back of its rising top line, capital strength and solid performances at both Acute Care and Behavioral Health segments.
UnitedHealth (UNH) Q4 Earnings Beat on Revenue Growth
by Zacks Equity Research
UnitedHealth's (UNH) Q4 results reflect strong contribution from its health benefits and service segments.
Why Should You Retain MEDNAX (MD) Stock in Your Portfolio?
by Zacks Equity Research
Riding high on its rising revenue stream and inorganic growth profile, MEDNAX (MD) holds potential to benefit its investors.
The Joint Corp. (JYNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOH vs. JYNT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MOH vs. JYNT: Which Stock Is the Better Value Option?
The Joint Corp. (JYNT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 50.00% and 0.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights: Joint, Anthem, Centene and UnitedHealth
by Zacks Equity Research
Zacks Industry Outlook Highlights: Joint, Anthem, Centene and UnitedHealth
Outlook for Health Insurance Industry Looks Sanguine
by Sapna Bagaria
Consolidation, increasing senior population, technological advancements and development of supplementary healthcare businesses poise the health insurance industry for secular growth.
MOH vs. JYNT: Which Stock Is the Better Value Option?
by Zacks Equity Research
MOH vs. JYNT: Which Stock Is the Better Value Option?
UnitedHealth's Stock Down in 1H19: What Lies Ahead in 2H?
by Zacks Equity Research
Regulatory disturbances weigh on UnitedHealth's (UNH) stock in the first half of 2019. However, the company is likely to get support from its strong business model.
3 Healthcare Stocks to Stay on Your Watch List for 2H19
by Zacks Equity Research
Banking on Medicaid and Medicare business, these three stocks should remain in your focus for the second half of 2019.